GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cannabis Suisse CSUI · USD

N/A · US listing · 🇺🇸 United States

Compare

0.01

—

Close of 30 Oct 2026, in USD

About Cannabis Suisse

From its filings with the US Securities and Exchange Commission

SEC filings

Cannabis Suisse is based in Jacksonville, Florida and is incorporated in Nevada. Its shares trade on OTC under the ticker CSUI. The SEC classifies its business as real estate. In the fiscal year to 31 May 2026, it reported revenue of $0 and net income of $122,739. At that date it held total assets of $407,479 and shareholders' equity of −$1.7m.

Read the filing on SEC.gov ↗

Company facts

Sector
N/A
Industry
N/A
Listed since
24 May 2018
Head office
10 NORTH NEWNAN STREET, JACKSONVILLE, FL, 32202
Incorporated in
NV
Classification
Real Estate
Filer status
Non-accelerated filer<br>Smaller reporting company

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Cannabis Suisse Corp produces THC-free CBD oils with 1500mg, 2500mg, and 3500mg concentrations for therapeutic use.
  • CBD Isolate Tinctures offer 1000mg CBD per 30ml bottle with 33.33mg per serving for precise dosing.
  • The company's retail branded cigarettes and health supplements target the US market with no THC content.

Weaknesses

  • Cannabis Suisse Corp's products are limited to CBD oils and tinctures without THC in the US market.
  • The company's IPO on 24 May 2018 restricts its market expansion opportunities.
  • Cannabis Suisse Corp's headquarters in Jacksonville, Florida, limits its global reach.

Opportunities

  • Cannabis Suisse Corp can expand its CBD oil flavors to include Creme de Menthe and Cherry Vanilla in new markets.
  • The US market offers growth potential for THC-free CBD products with therapeutic effects.
  • Cannabis Suisse Corp can leverage its 2018 IPO to attract more investors for product development.

Threats

  • Cannabis Suisse Corp faces regulatory challenges in the US market for CBD products.
  • The company's THC-free product line may face competition from similar CBD brands in the US.
  • Cannabis Suisse Corp's limited product range could hinder market penetration in the US.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.